A diabetes drug accidentally became the most sought-after weight loss medication in history, transforming not just waistlines but an entire pharmaceutical industry worth billions.

Story Overview

• Wegovy emerged from unexpected weight loss seen in diabetes patients taking Ozempic (semaglutide)
• FDA approved Wegovy in June 2021, with an oral version approved December 2025
• Clinical trials show 12% average body weight loss, double the efficacy of previous weight-loss drugs
• Off-label Ozempic use created shortages and sparked a pharmaceutical race worth billions
• Weight regain averages 67% after discontinuation, raising questions about long-term effectiveness

The Accidental Discovery That Changed Everything

Novo Nordisk researchers developed semaglutide in the early 2000s as a GLP-1 agonist targeting type 2 diabetes. The drug worked by mimicking hormones that regulate blood sugar, but clinical trials revealed an unexpected side effect: patients were losing significant weight. What started as a diabetes treatment averaging 6kg weight loss in patients became the foundation for a weight management revolution.

The company faced early hurdles with nausea and dosing challenges, nearly abandoning the project. Dr. Lotte Bjerre Knudsen and her team persisted through these setbacks, developing dose escalation protocols that would later prove crucial for both diabetes and obesity applications. Their persistence paid off when Ozempic received FDA approval for diabetes in 2017, setting the stage for what would become a blockbuster pivot.

From Off-Label Crisis to FDA Approval

By 2022, word spread about Ozempic’s weight loss effects, leading to widespread off-label prescribing that created severe shortages for diabetes patients. The 300% surge in GLP-1 prescriptions from 2018-2023 highlighted both the demand for effective obesity treatment and the problems with off-label use. This crisis accelerated Novo Nordisk’s development timeline for a dedicated obesity medication.

Wegovy received FDA approval in June 2021, followed by EU approval in January 2022. The medication uses higher doses of semaglutide specifically calibrated for weight management, showing average weight loss of 12% compared to previous drugs’ 5-6% efficacy rates. The approval came at a perfect time, as pandemic lifestyle changes had worsened America’s obesity epidemic.

Competition Heats Up the Weight Loss Market

Eli Lilly responded aggressively with tirzepatide, marketed as Zepbound for obesity and Mounjaro for diabetes. Clinical trials showed even more impressive results, with 21% average weight loss compared to Wegovy’s 12%. The competition intensified further with Lilly’s development of retatrutide, a triple-agonist showing 24% weight loss in Phase 2 trials.

Novo Nordisk’s stock price surged 260% following Wegovy’s success, making it Europe’s most valuable company. The pharmaceutical race has driven innovation at breakneck speed, with companies developing next-generation drugs that target multiple hormone pathways simultaneously. This competition benefits patients but raises questions about sustainable pricing and access.

Watch:

The Reality Behind the Revolutionary Results

Dr. Diana Thiara from UCSF calls Wegovy’s results “amazing and life-changing” for patients with obesity-related health risks. The drug provides cardiovascular benefits beyond weight loss, with FDA approving expanded indications in October 2025 for CV risk reduction. December 2025 brought another milestone with approval of an oral Wegovy formulation, offering patients an alternative to weekly injections.

However, the success story has significant caveats. Patients who discontinue Wegovy regain an average of 67% of their lost weight, highlighting the need for long-term commitment. Production shortages continue limiting access, while insurance coverage remains inconsistent. The high cost puts the medication out of reach for many patients who could benefit most from treatment.

Your instant doctor companion – online 24 hours a day.

Sources:

From Diabetes to Obesity Drugs: How Ozempic and Mounjaro Became Wegovy and Zepbound
The Ozempic Era – MUSC
RX History: GLP-1s – Innovative RX Strategies
Semaglutide – Wikipedia
PMC Article on GLP-1 Agonists
Weight Loss Drugs: Too Good to Be True? – UCSF Magazine